ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /化合物

ナルトレキソン塩酸塩

Naltrexone Hydrochloride

HCID 5485201
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
16676-29-2
標準SMILES
Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
InChIKey
RHBRMCOKKKZVRY-ITLPAZOVSA-N
分子式
C20H24ClNO4
平均分子量
377.9 g/mol
単同位体質量
377.13938593

概要

Naltrexone hydrochloride is a hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid. it is a -opioid receptor antagonist that is used to treat alcohol dependence. It has a role as a central nervous system depressant, a mu-opioid receptor antagonist and an antidote to opioid poisoning. It contains a naltrexone(1+).

名称と識別子

優先名称
Naltrexone Hydrochloride
IUPAC
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
現地名
ナルトレキソン塩酸塩
英語名
Naltrexone hydrochloride
分子式
C20H24ClNO4
分子量
377.87

名称と別名

Naltrexone hydrochloride16676-29-2Naltrexone HclDepadenaltrexone.HClEn 1639AEN-1639AN-Cyclopropylmethyl-noroxymorphone hydrochlorideZ6375YW9SFEN-1639A (AS HYDROCHLORIDE)(5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride17-(Cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-one hydrochloride
名称をさらに表示
ナルトレキソン塩酸塩17-(シクロプロピルメチル)-4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン·塩酸塩ナルトレキソン 塩酸塩17-(シクロプロピルメチル)-4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン・塩酸塩ReVianih8503en1639aNalorexAntaxone4-D-butylCcris 1168NSC 409767Nalmefene-3
Naltrexone hydrochloride (USP)Naltrexone hydrochloride [USP]CHEBI:134687DTXSID50937236TROXYCA COMPONENT NALTREXONE HYDROCHLORIDECONTRAVE COMPONENT NALTREXONE HYDROCHLORIDETrexonilRefChem:56740

物性

構造計算による物性補完中

極性表面積
70 Ų
水素結合供与体数
3
水素結合受容体数
5
回転可能結合数
2
重原子数
26
形式電荷
0
複雑度
621

実験および物理化学的性質

Solubility>56.7 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Alcohol Deterrents; Narcotic Antagonists

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal DrugsActive Ingredients (Naltrexone Hydrochloride) -> FDA Greenbook
Collision Cross Section176 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
274 · 274-2760C
貯蔵温度
2 · 2-8°C
溶解性
2 O: · H2O: 50 mg/mL 無色透明
外見
powder
色
ホワイトからオフホワイト
水溶解度
50 mg/mlで水に溶けます。 · 50mg/mlで水に溶けます。
Merck
13 · 13,6389
BRN
3580333 · 3580333
InChIKey
RHBRMCOKKKZVRY-LNTCFJBQNA-N
SMILES
O[C@]12CCC(=O)[C@]3([H])OC4=C(C=CC5C[C@@]1([H])N(CC1CC1)CC[C@@]23C4=5)O.Cl |&1:1,6,15,24,r|

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P233, P260, P261, P264, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P333+P317, P342+P316, P362+P364, P403, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 83 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (97.6%)

毒性情報

TreatmentPatients should be treated symptomatically in a closely supervised environment. (L1712)
Health Effects · 1 件

Tolerance can develop, in which the person needs larger doses to achieve the desired effect; this can lead to overdose and death. Accidents or injury can also occur due to the side effects of loss of coordination, slowed reaction time, sleepiness and impaired judgment. Drugs in this category have a high potential for physical and psychological dependence.

Exposure RoutesAlthough well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
Toxicity Summary · 1 件

Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, kappa, and delta receptors in the CNS, with the highest affintiy for the mu receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-beta-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug.

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Hepatic. When administered orally, naltrexone undergoes extensive biotransformation and is metabolized to 6 beta-naltrexol (which may contribute to the therapeutic effect) and other minor metabolites. Route of Elimination: Both parent drug and metabolites are excreted primarily by the kidney (53% to 79% of the dose), however, urinary excretion of unchanged naltrexone accounts for less than 2% of an oral dose and fecal excretion is a minor elimination pathway. The renal clearance for naltrexone ranges from 30 to 127 mL/min and suggests that renal elimination is primarily by glomerular filtration. Half Life: 4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.

FDA Pharmacological Classification · 2 件

NALTREXONE HYDROCHLORIDE

Opioid Antagonists [MoA]; Opioid Antagonist [EPC]

MeSH Pharmacological Classification · 2 件

Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism.

Agents inhibiting the effect of narcotics on the central nervous system.

用途と製造

Uses · 1 件

Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
応用分野 · 2 件

Naltrexone hydrochloride is a potent, long-acting, orally-effective narcotic antagonist useful in the management of narcotic addiction.

関連反応

7 件
反応記録を作成
HRID 430704 の反応式
HRID 430704反応物としてuspto-grants-2001_11
HRID 567431 の反応式
HRID 567431反応物としてuspto-grants-2001_01
HRID 651048 の反応式
HRID 651048反応物としてuspto-grants-2001_08
HRID 845825 の反応式
HRID 845825反応物としてuspto-grants-1988_07
HRID 845826 の反応式
HRID 845826反応物としてuspto-grants-1988_07
HRID 1037635 の反応式
HRID 1037635生成物としてuspto-grants-2013_10
HRID 2370712 の反応式
HRID 2370712生成物としてuspto-grants-2014_04

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
16676-29-2
PubChem CID
5485201
DTXSID
DTXSID50937236
ChEMBL
CHEMBL1201149
ChEBI
CHEBI:134687
UNII
Z6375YW9SF
EC Number
240-723-0
CAS データベース
16676 · 16676-29-2(CAS DataBase Reference)

化学的性質

化学的特性White Crystalline Powder

Signs and SymptomsHigh doses of naltrexone (generally ≥1,000 mg/kg) produce salivation, depression/reduced activity, tremors, and convulsions.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Naltrexone hydrochloride

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 1,100-1,550 mg/kg (oral, mouse) LD50: 1,450 mg/kg (oral, rat) LD50: 1,490 mg/kg (oral, guinea pig)

安全データ

F
8-10
wgk
3
rtecs
QD2160000
毒性
guinea pig,LD50,oral,1490mg/kg (1490mg/kg),Medicamentos de Actualidad. Vol. 21, Pg. 264, 1985.
hs_code
2932.99.7000
risk_code
22
hazard_code
Xn
safety_code
22-36
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids
説明

使用Naltrexone hydrochloride has been used:as an opioid antagonist, to analyse its effect on ethanol preference using Caenorhabditis elegans as a model.to determine its effectiveness in reducing the preference for substance of abuse (SOA) like nicotine and cocaine using Caenorhabditis elegans as a model.in the preparation of combinatorial drug, PXT3003 for treating Charcot-Marie-Tooth disease 1A (CMT1A) transgenic rat model Pmp22.

調製方法

純化方法This narcotic antagonist has been purified by recrystallisation from MeOH and dried in air. The free base has m 168-170o after recrystallisation from Me2CO. [Cone et al. J Pharm Sci 64 618 1975, Gold et al. Med Res Rev 2 211 1982.]

上流・下流製品情報

下流製品

Naltrexone 3-Methyl Etherナルトリンドール塩酸塩